ClearPoint Neuro Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Item · Page | ||
|---|---|---|
| PART I | ||
| 1. | Business. | 3 |
| 1A. | Risk Factors. | 17 |
| 1B. | Unresolved Staff Comments. | 39 |
| 1C. | Cybersecurity. | 40 |
| 2. | Properties. | 40 |
| 3. | Legal Proceedings. | 40 |
| 4. | Mine Safety Disclosures. | 40 |
| PART II | ||
| 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. | 41 |
| 6. | Reserved. | 41 |
| 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. | 42 |
| 7A. | Quantitative and Qualitative Disclosures About Market Risk. | 48 |
| 8. | Financial Statements and Supplementary Data. | 48 |
| 9. | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. | 48 |
| 9A. | Controls and Procedures. | 49 |
| 9B. | Other Information. | 49 |
| 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspection | 49 |
| PART III | ||
| 10. | Directors, Executive Officers and Corporate Governance. | 50 |
| 11. | Executive Compensation. | 50 |
| 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. | 50 |
| 13. | Certain Relationships and Related Transactions, and Director Independence. | 51 |
| 14. | Principal Accounting Fees and Services. | 51 |
| PART IV | ||
| 15. | Exhibits, Financial Statement Schedules. | 52 |
Trademarks, Trade Names and Service Marks
ClearPoint Neuro®, ClearPoint®, SmartFlow®, SmartFrame®, SmartGrid®, Inflexion®, SmartTwist™, SmartTip™, ClearPoint Maestro®, SmartFrame Array®, SmartFrame OR™, ClearPoint Neuro Orchestra™, ClearPoint Prism®, SmartFlow Flex™, ClearPointer™, When Your Path is Unclear, We Point The Way®, and ClearPoint Advanced Laboratories™ are all trademarks of ClearPoint Neuro, Inc. Any other trademarks, trade names or service marks referred to in this Annual Report are the property of their respective owners.
Company Names Used in this Annual Report
As used in this Annual Report, we, us, our, the Company or ClearPoint Neuro refer to ClearPoint Neuro, Inc. and its affiliates; Siemens refers to Siemens Healthineers AG and its affiliates; Boston Scientific refers to Boston Scientific Corporation and its affiliates; Brainlab refers to Brainlab AG and its affiliates; UCB refers to UCB Biopharma SRL and its affiliates; CLS refers to Clinical Laserthermia Systems AB and its affiliates; IMRIS refers to IMRIS, Deerfield Imaging, Inc. and its affiliates; PTC refers to PTC Therapeutics, Inc. and its affiliates; Philips refers to Koninklijke Philips N.V. and its affiliates; Abbott refers to Abbott Laboratories and its affiliates; Elekta refers to Elekta AB and its affiliates; NE Scientific refers to NE Scientific, LLC and its affiliates; NeuroPace refers to NeuroPace, Inc. and its affiliates; Medtronic refers to Medtronic plc and its affiliates; UCSF refers to the University of California, San Francisco; and Johns Hopkins refers to Johns Hopkins University.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.